Tivic Health® Systems, Inc. (Nasdaq: TIVC), a leader in bioelectronic medicine, has appointed Lisa Wolf as its Interim Chief Financial Officer (CFO), effective October 1, 2024. Wolf succeeds Kimberly Bambach, who has served as interim CFO since April 2023 and will continue with Tivic in an advisory role focusing on strategic transactions and special projects.
“Lisa has been a valuable member of Tivic’s finance team for over two years, and I’m excited for her to step into this crucial role,” said Jennifer Ernst, CEO of Tivic Health. “I look forward to working with her as we advance our bioelectronic therapeutics.”
With 30 years of financial leadership experience, Wolf has a strong grasp of Tivic’s financial operations and has previously worked at Murdock Martell, Resonant, Inc., and Arthur Andersen. Her expertise will be instrumental in guiding Tivic through its next growth phase.
Bambach’s ongoing advisory role will ensure a smooth transition and continued access to her expertise in transactions and integrations.
“We are also thankful for Kimberly Bambach’s significant contributions over the past 18 months as we restructured to meet evolving market needs. I’m glad she will continue to support us in her advisory role,” added Ernst.
About Tivic Health
Tivic Health is advancing bioelectronic medicine with technologies that stimulate nerve structures to treat inflammatory chronic health conditions. The company’s first product, ClearUP, is an FDA-approved, award-winning handheld device for sinus relief. ClearUP offers a non-invasive, drug-free solution and is available through online retailers and commercial distributors.
